[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neonatal-outcomes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neonatal-outcomes":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100641672","systematic-screening-of-lower-genital-tract-infections-100641672",false,"NCT07592286","Systematic Screening of Lower Genital Tract Infections","Systematic Screening of Lower Genital Tract Infections in Pregnant Women for Gestational and Neonatal Outcomes: a Randomized Controlled Trial","Inclusion Criteria:\n\n* First-trimester pregnant women.\n* Receiving care at the Women's Health service.\n* Willingness to participate in the study.\n\nExclusion Criteria:\n\n#No specific exclusion criteria.\n\nThe study has not started yet and no participants have been enrolled. The term \"low-risk\" was removed because the study will recruit pregnant women in general","FEMALE","12 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"NA","Introduction: The investigation of systematic screening for asymptomatic genital infections in pregnant women is justified by the relevance of these conditions in determining adverse neonatal outcomes, such as prematurity, low birth weight, and perinatal morbidity and mortality. Despite its importance, previous studies have shown inconsistent results, largely due to methodological limitations related to sample size, lack of standardized treatment protocols, and insufficient follow-up of pregnant women. There is also divergence among national and international guidelines, which vary between universal and selective recommendations, highlighting gaps in the standardization of clinical practices.\n\nObjectives: To investigate the effectiveness of implementing systematic screening protocol for asymptomatic genital infections in pregnant women in preventing adverse gestational and neonatal outcomes. The specific objectives are: to identify the most prevalent infections in this group; to evaluate the relationship between treatment and the incidence of complications; to compare outcomes between participants assigned to systematic screening and those receiving standard care and to propose recommendations for clinical practice and health policies based on a critical review of the literature and the results obtained.\n\nMethods: This is a randomized controlled trial that will recruit 250 pregnant women, followed from the first trimester until delivery. Participants will be randomized into two groups: an intervention group, undergoing systematic screening with protocol-guided treatment, and a control group, managed according to current standard care practices, following the municipality's protocol for screening and treatment of genital infections. Primary outcomes include preterm birth, preterm premature rupture of membranes, low birth weight, intra-amniotic infection, puerperal infection, neonatal infection, and fetal and neonatal mortality. Statistical analysis will follow the intention-to-treat principle, and differences in outcomes between groups will be estimated.\n\nExpected Results: This study is expected to provide evidence on whether systematic screening reduces (or does not reduce) maternal and neonatal complications. The randomized controlled trial will be prospectively registered prior to the enrollment of the first participant, in accordance with current ethical standards.\n\n\\*\\* The study has not started yet and no participants have been enrolled. The term \"low-risk\" was removed because the study will recruit pregnant women in general",[26,27,28,29,30],"Neonatal Outcomes","Pregnancy Complications, Infectious","Premature Birth","Premature Rupture of Fetal Membranes","Pregnancy",[32,33,34],"screening","lower genital tract infections","pregnancy","NOT_YET_RECRUITING","2026-06-15",{"date":38,"type":39},"2026-06-17","ACTUAL",{"date":41,"type":20},"2026-07-15",{"date":43,"type":20},"2028-12-30",{"name":45,"class":46},"Universidade Federal do Pampa","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100628056","phase-2-caffeine-for-infants-born-at-28-to-34-weeks-receiving-respiratory-support-100628056","NCT07456670","Caffeine for Infants Born at 28 to 34 Weeks Receiving Respiratory Support","Caffeine Therapy in Preterm Infants Born at 28-34 Weeks: A Pilot Placebo-Controlled Randomized Controlled Trial","CARES-Pilot","Inclusion Criteria:\n\n* Infant born at a gestational age between 28+0 and 34+6 weeks.\n* Admitted to the Neonatal Intensive Care Unit (NICU) within the first 72 hours of life.\n* Requiring either invasive respiratory support (mechanical ventilation) or non-invasive respiratory support (e.g., CPAP, High Flow Nasal Cannula) within the first 72 hours of life.\n* Informed consent obtained from parent(s) or legal guardian(s).\n\nExclusion Criteria:\n\n* Presence of dysmorphic features or major congenital malformations that adversely affect life expectancy.\n* Known or strongly suspected cyanotic heart disease.\n* Infants born at \\\u003C28 weeks' gestational age (due to high risk of apnea requiring routine caffeine).\n* Late preterm infants born at ≥35+0 weeks' gestational age (due to short NICU stay not allowing for a safe caffeine-free period before discharge).","ALL","0 Days","28 Days",{"count":59,"type":20},62,[61],"PHASE2","The goal of this pilot clinical trial is to test if it is possible to conduct a larger study on the use of caffeine in preterm infants who need help with their breathing. It will also look at whether caffeine helps these infants get healthy enough to leave the hospital sooner.\n\nThe main questions the researchers aim to answer are:\n\nCan the investigators successfully recruit and keep enough participants in the study? Do the medical teams follow the study drug instructions correctly? Does caffeine reduce the total time infants spend in the Neonatal Intensive Care Unit (NICU)? Researchers will compare caffeine to a placebo (a look-alike substance with no active medicine) to see if caffeine is a helpful treatment for babies born between 28 and 34 weeks of gestation who are using a breathing machine or oxygen.\n\nParticipants will:\n\nBe randomly assigned to receive either caffeine or a placebo through an IV or a feeding tube.\n\nReceive the study treatment once a day as long as they require respiratory support (and for 24 hours after they stop).\n\nBe monitored by the research team for clinical outcomes like feeding progress, breathing stability, and growth until they are discharged from the hospital.",[64,65,26],"Preterm Birth","Caffeine",[65,67,68,69,70,71],"Neonatal Intensive Care Unit","Prematurity","RCT","NICU","Pilot Study","2026-03-06",{"date":74,"type":39},"2026-03-10",{"date":76,"type":20},"2026-04-01",{"date":78,"type":20},"2028-03-31",{"name":80,"class":46},"Queen's University",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":81},"100619378","virtual-reality-versus-intravenous-dexmedetomidine-on-maternal-anxiety-stress-hemodynamics-and-neonatal-outcomes-during-cesarean-section-100619378","NCT07343843","Virtual Reality Versus Intravenous Dexmedetomidine on Maternal Anxiety, Stress, Hemodynamics, and Neonatal Outcomes During Cesarean Section","Effect of Virtual Reality Versus Intravenous Dexmedetomidine on Maternal Anxiety, Stress, Hemodynamics, and Neonatal Outcomes During Cesarean Section","Inclusion Criteria:\n\n* Age over 18 years old.\n* American Society of Anesthesiologists (ASA) physical status II.\n* Scheduled for elective cesarean section (CS) delivery under Central Neuraxial Blockade.\n* Provide informed consent and agree to participate in the study.\n\nExclusion Criteria:\n\n* Patient's refusal\n* Patient known have contraindications for Regional Anesthesia as infection at the site of injection, severe coagulopathy or allergy to local anesthetics.\n* Patient with psychiatric disorders.\n* Sensory impairment (blindness, deafness).\n* Any technical problem preventing proper fitting of the glasses to the patient face.\n* Patients with cognitive impairment, epilepsy or with claustrophobia\n* Patients with suspected eye infection\n* Signs of active labor.\n* Pregnancy related-diseases or antepartum hemorrhage.\n* Presence of Fetal distress.","18 Years",{"count":91,"type":20},52,[23],"This study aims to compare the efficacy of intravenous dexmedetomidine infusion versus virtual reality (VR) in reducing maternal anxiety, stress, and hemodynamic instability during cesarean section and their effects on neonatal outcome as respiration and heart rate.",[95,96,97,98,99,26,100],"Virtual Reality","Dexmedetomidine","Maternal Anxiety","Stress","Hemodynamics","Cesarean Section","RECRUITING","2026-01-17",{"date":104,"type":39},"2026-01-21",{"date":102,"type":39},{"date":107,"type":20},"2026-07-01",{"name":109,"class":46},"Benha University"]